R R

What Is Opzelura?

Opzelura is a prescription topical cream containing ruxolitinib 1.5%, a Janus kinase inhibitor. It is approved for certain patients with mild to moderate atopic dermatitis and for nonsegmental vitiligo. Atopic dermatitis treatment is approved for non-immunocompromised adults and children aged two years and older whose condition is inadequately controlled by topical prescription treatments or when those treatments are not advisable. Treatment for nonsegmental vitiligo is approved for patients aged 12 years and older. Opzelura is applied to affected skin and is not intended for use inside the eyes.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Opzelura?

Opzelura is a prescription topical cream containing ruxolitinib 1.5%, a Janus kinase inhibitor. It is approved for certain patients with mild to moderate atopic dermatitis and for nonsegmental vitiligo. Atopic dermatitis treatment is approved for non-immunocompromised adults and children aged two years and older whose condition is inadequately controlled by topical prescription treatments or when those treatments are not advisable. Treatment for nonsegmental vitiligo is approved for patients aged 12 years and older. Opzelura is applied to affected skin and is not intended for use inside the eyes.

read more about opzelura ...

Copy this HTML:

Copy HTML Copied!

How Does Opzelura Work?

Opzelura contains ruxolitinib, which inhibits Janus kinase 1 and Janus kinase 2. These enzymes participate in signaling pathways involved in inflammation and immune activity. Blocking their activity can reduce inflammatory symptoms associated with atopic dermatitis, including itching and redness. In nonsegmental vitiligo, the medication interferes with immune signaling that contributes to pigment loss, allowing repigmentation in some patients over time. Treatment response varies, and Opzelura does not permanently cure either condition.

What Skin Conditions Does Opzelura Treat?

Opzelura is approved for short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients aged two years and older who meet the labeled treatment criteria. It is also approved for nonsegmental vitiligo in patients aged 12 years and older. Atopic dermatitis involves inflammatory skin symptoms such as itching and redness, while vitiligo causes areas of skin to lose pigmentation. Opzelura is not approved for every inflammatory skin disorder. Combining it with biologic therapies, other JAK inhibitors, or potent immunosuppressants is not recommended.

How Should Opzelura Cream Be Applied?

Opzelura is applied as a thin layer to affected skin twice daily. For atopic dermatitis, treatment is limited to areas covering no more than 20% of body surface area and should stop when symptoms resolve. For nonsegmental vitiligo, treatment is limited to no more than 10% of body surface area, and repigmentation can require several months. Quantity limits vary by age and indication. Opzelura should not be applied under occlusive dressings or used inside the eyes, mouth, or vagina. Follow the prescribed treatment plan and product-specific quantity restrictions.

What Are the Side Effects and Warnings of Opzelura?

Possible adverse effects include application-site reactions, acne, headache, and upper respiratory infections, with frequencies differing by indication and age. Opzelura carries boxed warnings related to serious infections, mortality, malignancy, major cardiovascular events, and thrombosis associated with JAK inhibitor treatment. Although Opzelura is applied to the skin, these warnings require careful assessment of individual risk factors. Patients should report severe infections, unusual skin changes, chest pain, or symptoms suggesting a blood clot. The cream is not intended for ophthalmic use.

Common Questions About Opzelura

Is Opzelura a steroid cream?

No. Opzelura contains ruxolitinib, a topical JAK1 and JAK2 inhibitor. It is not a corticosteroid.

Can Opzelura treat vitiligo?

Yes. Opzelura is approved for nonsegmental vitiligo in adults and children aged 12 years and older. Repigmentation can take several months.

Can children use Opzelura for eczema?

Yes. Opzelura is approved for certain non-immunocompromised children aged two years and older with mild to moderate atopic dermatitis. Age-specific quantity restrictions apply.

Can Opzelura be applied near the eyes?

Opzelura should not be placed inside the eyes. Patients should follow their dermatologist's directions about treatment areas and avoid accidental eye exposure.

References

DailyMed - OPZELURA (ruxolitinib) cream. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24da5509-6631-4795-9d42-273faecd08e7. Date Accessed October 22, 2026.

FDA Approves Topical Treatment Addressing Repigmentation in Vitiligo in Patients Aged 12 and Older. U.S. Food and Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older. Date Accessed October 22, 2026.

Ruxolitinib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Ruxolitinib. Date Accessed October 22, 2026.

Ruxolitinib Cream. Cleveland Clinic. https://my.clevelandclinic.org/health/drugs/23812-ruxolitinib-topical-cream. Date Accessed October 22, 2026.

Ruxolitinib Topical. MedlinePlus. https://medlineplus.gov/druginfo/meds/a621053.html. Date Accessed October 22, 2026.